MaxCyte, Inc.
Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $1.25
- 52-Week Range
- $0.64 – $1.80
- Market Cap
- $132.16M
- P/E (TTM)
- —
- EPS (TTM)
- -0.26
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.88
- PEG Ratio
- —
- Return on Equity
- -16.90%
- Return on Assets
- -9.28%
- Gross Margin
- 80.98%
- Operating Margin
- -85.47%
- Profit Margin
- -81.40%
- Current Ratio
- 7.83
- Debt/Equity
- 0.11
- Total Debt
- $16.89M
- Free Cash Flow
- $-14.98M
- Revenue Growth
- 48.70%
- Earnings Growth
- —
- Enterprise Value
- $44.67M
Market Snapshot
About
MaxCyte develops and commercializes cell-engineering platforms using proprietary electroporation technology for loading cells with biomolecules. The company enables biopharmaceutical developers to create cell-based therapeutics including CAR-T and other immunotherapies.